Top 10 CRISPR Stocks to Buy Now

Page 8 of 10

3. Intellia Therapeutics, Inc. (NASDAQ:NTLA

Number of Hedge Fund Holders: 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best CRISPR stocks to buy. Citizens JMP reaffirmed its Market Perform rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) on June 17. The update came in response to encouraging three-year follow-up data from the company’s Phase I trial of NTLA-2002, now known as Lonvoguran ziclumeran (Lonvo-z), in patients with hereditary angioedema (HAE). The treatment possesses a solid safety record, with only brief side effects being noted.

According to Citizens JMP, the findings “underline durability and shows the value proposition to patients that can potentially live disease free.” However, despite the encouraging long-term results from the HAE therapy research, the firm believes that Intellia’s stock is “fairly valued” at current levels.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a biotech company at the forefront of CRISPR-Cas9 gene-editing technology, developing cutting-edge treatments for both in vivo and ex vivo applications. Its main initiative, NTLA-2001, aims to treat transthyretin amyloidosis, a disease that is currently incurable. Targeting hereditary angioedema (HAE), NTLA-2002 is another promising medication in development.

Page 8 of 10